Chesapeake Oncology Hematology Associates

What Chesapeake Oncology Hematology Associates does

Chesapeake Oncology Hematology Associates (COHA) is a private, physician-owned community oncology and hematology practice operating four clinic locations across central Maryland (Glen Burnie/Tate Cancer Center, Columbia, Annapolis, and Stevensville/Eastern Shore). The practice delivers a full spectrum of cancer and blood disorder services including chemotherapy, immunotherapy, radiation therapy (IMRT, IGRT, SBRT/SABR, SRS, proton therapy), iron infusions, and treatment across 15 cancer types, supported by an in-house diagnostic laboratory and an on-site physician dispensing pharmacy. Each clinic maintains a chemotherapy infusion suite staffed by oncology nurses, and the practice holds QOPI certification as a Quality Oncology Practice Initiative site.

The practice is staffed by 7 board-certified physicians (medical oncologists, hematologists, and radiation oncologists) plus 2 advanced practice providers and over 30 clinical and administrative staff, with credentials drawn from institutions such as Johns Hopkins, Georgetown, Memorial Sloan Kettering, and the University of Maryland. Revenue is generated through fee-for-service billing to a broad payer mix including Medicare, Medicaid, Aetna, CareFirst, United Healthcare, and CIGNA, supplemented by clinical research collaborations with the University of Maryland. Distribution is via physician referrals, self-referrals, hospital-based inpatient consultations at Anne Arundel Medical Center, Howard County General Hospital, and Baltimore Washington Medical Center, and a recently launched telemedicine channel.

As of November 1, 2025, COHA recapitalized and joined Chesapeake Urology Associates on the OneOncology platform (a United Urology Group affiliate), integrating oncology and urology services under one regional platform to expand access to advanced therapies and clinical trials across the DMV region. COHA retains its brand identity and operates under a physician partnership model, with Provident Healthcare Partners advising on the transaction.

Name

Chesapeake Oncology Hematology Associates

Legal name

Chesapeake Oncology-Hematology Associates, P.A.

Website

https://cohamed.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

51–100 employees

Short description

Chesapeake Oncology Hematology Associates is a private Maryland community oncology and hematology practice operating four clinic locations, delivering chemotherapy, immunotherapy, radiation therapy, and supportive care across 15 cancer types to patients in the DMV region.

Ownership category

akta.pro rank

Product category

Outpatient Oncology and Hematology Services

NAICS

Offices of Physicians (except Mental Health Specialists) (621111), Ambulatory Health Care Services (621)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Hematologic Oncology (Leukemia/Lymphoma/Myeloma) (HLAKAFAD), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

Keywords

• Medical oncology services
• Hematology treatment services
• Cancer treatment center
• Chemotherapy infusion therapy
• Radiation oncology services

Headquarters

HQ city

Glen Burnie

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D

Revenue model

1. Patient Care Services: COHA generates revenue through patient care services billed to insurance providers and government healthcare programs (Medicare, Medicaid). Services include chemotherapy, radiation therapy, immunotherapy, iron infusions, in-house laboratory testing, and physician dispensing pharmacy.
2. Clinical Trials and Research: COHA collaborates with the University of Maryland to provide access to clinical trials, potentially generating research funding or referral-based revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Chesapeake Oncology-Hematology Associates is a private medical oncology and hematology practice providing diagnosis, treatment, and management of cancer and blood disorders across four Maryland cancer centers. Core services include chemotherapy, immunotherapy, radiation therapy (including IMRT, IGRT, SBRT, SRS, and proton therapy), iron infusions, on-site laboratory testing, and a physician dispensing pharmacy, delivered by seven board-certified oncologists and hematologists with QOPI quality certification.

Product overview

Chesapeake Oncology-Hematology Associates (COHA) is a leading oncology group practice offering comprehensive medical oncology and hematology services across Maryland through four medical centers (Tate Cancer Center in Glen Burnie, Columbia Cancer Center, Annapolis Cancer Center, and Eastern Shore Cancer Center in Stevensville). The practice provides a full spectrum of cancer treatment services including chemotherapy, immunotherapy, radiation therapy, iron infusions, in-house laboratory testing, and an on-site physician dispensing pharmacy. COHA treats 15 types of cancer including lung, breast, colorectal, pancreatic, prostate, liver, gynecologic, bladder, skin, stomach, central nervous system, thyroid, and blood cancers. Services are delivered by seven physicians and over 30 staff members, with each office featuring infusion centers staffed by skilled oncology nurses. The practice is QOPI certified and partners with the University of Maryland for clinical trials access.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Oncology Services Comprehensive medical oncology services for the diagnosis and treatment of cancer, including lung, breast, colorectal, pancreatic, prostate, liver, gynecologic, bladder, skin, head and neck, central nervous system, thyroid, stomach, leukemia, and non-Hodgkin's lymphoma, using chemotherapy, targeted therapies, and advanced treatment protocols. Provided to individual cancer patients in Maryland through COHA's four cancer centers.
• Hematology Services Specialized hematology services for the diagnosis and treatment of blood disorders including anemia, blood clots, leukemia, and lymphoma. Delivered by board-certified hematologists across COHA's Maryland cancer centers.
• Chemotherapy Treatment Drug therapy that destroys fast-growing cancer cells, administered intravenously or orally, used alone or combined with surgery, radiation, or immunotherapy. Available to oncology patients at all four COHA Maryland cancer centers.
• Immunotherapy Treatment Advanced cancer therapy that uses the body's immune system to identify and eliminate cancer cells at the cellular level. Offered to oncology patients at COHA's Maryland cancer centers.
• Radiation Therapy Cancer treatment using controlled high-energy radiation to destroy cancer cells, including IMRT, IGRT, SBRT, SABR, SRS, and proton therapy techniques. Delivered to oncology patients at Tate Cancer Center in Glen Burnie.
• Iron Infusions Intravenous iron delivery for iron-deficiency anemia treatment when oral supplements are insufficient. Offered to patients at all COHA office locations across Maryland.
• In-House Laboratory Diagnostics On-site diagnostic laboratory providing CBC, chemistry, tumor markers, iron studies, and B12 testing with timely results to guide treatment decisions. Available to COHA patients across cancer centers.
• Physician Dispensing Pharmacy On-site pharmacy dispensing oral cancer and supportive medications directly to patients during office visits to improve medication adherence and care coordination for COHA patients.
• Clinical Trials Access (via University of Maryland Partnership) Access to cancer clinical trials via COHA's partnership with the University of Maryland, connecting COHA patients to investigational therapies and over 1,000 healthcare professionals and cancer experts.
• Telemedicine Visits Telemedicine visit option available to current COHA patients for remote access to oncology and hematology care.

Quantifiable outcome

• Over 25 years of oncology and hematology service delivery in Maryland communities
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Chesapeake Urology Associates (CUA)coreStrategic or Co-development Partner · 1 November 2025COHA recapitalized and partnered with Chesapeake Urology Associates (CUA), an affiliate of United Urology Group operating on the OneOncology platform. The transaction integrates oncology and urology services under one platform to expand access, improve care coordination, and enhance patient outcomes in the DMV region. As of November 1, COHA joined CUA.
• OneOncologycoreStrategic or Co-development Partner · 1 November 2025COHA operates on the OneOncology platform as an affiliate of United Urology Group. OneOncology is a healthcare platform supporting independent oncology practices with technology, operational resources, and strategic partnerships to enable high-quality, community-based cancer care.
• University of MarylandcoreStrategic or Co-development PartnerCOHA partnered with the University of Maryland, a renowned teaching hospital that provides cancer care and clinical trials. COHA physicians and clinicians collaborate with more than 1,000 healthcare professionals and cancer experts at the University of Maryland, which helps provide treatment with the best results possible.
• United Urology GroupminorStrategic or Co-development PartnerChesapeake Urology Associates is an affiliate of United Urology Group. COHA's partnership with CUA connects them to the broader United Urology Group network.
• Provident Healthcare PartnersminorOthersProvident Healthcare Partners advised Chesapeake Oncology-Hematology Associates in its recapitalization and partnership with Chesapeake Urology Associates.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• OneOncology: National platform supporting independent community oncology practices with technology, operations, and payer partnerships. COHA is an affiliate; comparable as a parent platform that determines the strategic ceiling for affiliates.
• Johns Hopkins Sidney Kimmel Cancer Center: NCI-designated academic cancer center with deep oncology brand and clinical trial portfolio. Sets the upper competitive benchmark in the Maryland market and employs several COHA physicians in clinical affiliations.
• Florida Cancer Specialists & Research Institute: Largest US community oncology practice; provides chemotherapy, immunotherapy, radiation, in-house labs, and clinical trials at scale. Useful benchmark for what a mature multi-site community oncology platform looks like.
• Tennessee Oncology: Large multi-site community oncology/hematology practice affiliated with OneOncology, providing a same-platform comparator for COHA's structural and economic trajectory.

Direct peers

• ASTERA Cancer Care: Multi-specialty community oncology platform in the Mid-Atlantic offering medical oncology, hematology, radiation, and clinical trials across multiple sites—directly comparable operating model to COHA.
• Maryland Oncology Hematology: Large community oncology and hematology practice serving Maryland/DC/Virginia with similar service lines (chemo, infusion, clinical trials). Closest geographic and service-line comparable to COHA.
• Compass Oncology: Multi-site community oncology practice in Oregon/Washington offering medical oncology, hematology, radiation, and clinical trials—analogous operating model in a different geography.
• Chesapeake Urology Associates: COHA's new affiliated partner on the OneOncology platform; provides integrated urology care and operates under the same parent platform, enabling direct comparison of unit economics and referral dynamics.
• Virginia Cancer Specialists: Affiliated with The US Oncology Network, this is a large multi-site community oncology/hematology practice in Northern Virginia offering chemotherapy, immunotherapy, radiation, and clinical trials—similar model to COHA but larger scale.

Regional players

• University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center: NCI-designated academic cancer center in Baltimore. COHA's clinical trial partner and a competing referral destination for complex oncology cases in the same DMV geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/COHA_Contact
• Facebookfacebook.com/cohamed
• LinkedInlinkedin.com/company/chesapeake-oncology-hematology-associates-p-a

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chesapeake Oncology Hematology Associates